Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy-Reference-Cited by-同舟云学术

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy

Published:2019-05-10 Issue:12 Volume:129 Page:
ISSN:0023-852X
Container-title:The Laryngoscope
language:en
Short-container-title:The Laryngoscope

Author:

Hwang Victoria¹^ORCID,Mendez Eduardo²,Chow Laura Q. M.³,Futran Neal David²,Andersen Peter⁴,Li Ryan⁴,Divi Vasu⁵,Rodriguez Cristina P.³

Affiliation:

1. Loyola University Chicago Stritch School of Medicine Maywood Illinois

2. Department of OtolaryngologyFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington Seattle Washington

3. Department of Medicine, Division of Medical OncologyFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington Seattle Washington

4. Department of OtolaryngologyOregon Health and Sciences University Portland Oregon

5. Department of OtolaryngologyStanford University Medical Center Palo Alto California U.S.A.

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lary.27902

Reference12 articles.

1. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

2. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

4. LBA8_PR KEYNOTE‐048: phase III study of first‐line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [abstract];Burtness B;Annals of Oncol,2018

5. An open‐label, multicohort, phase 1/2 study in patients with virus‐associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN) [abstract LBA46];Ferris R;Annals of Oncol,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?;Military Medical Research;2024-04-18

2. Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer;Cancer;2023-10-03

3. Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review;Special Care in Dentistry;2023-06-07

4. Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study;BMC Cancer;2022-12-13

5. Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer;Head & Neck;2021-01-08